Clinical Study of Xingnaojing Injection for Treatment of Septic Encephalopathy
10.13359/j.cnki.gzxbtcm.2015.05.005
- VernacularTitle:醒脑静注射液治疗脓毒性脑病的临床研究
- Author:
Shuming ZHENG
;
Xinfeng LIN
- Publication Type:Journal Article
- Keywords:
Septic encephalopathy/TCM-WM therapy;
Xingnaojing Injection/therapeutic use
- From:
Journal of Guangzhou University of Traditional Chinese Medicine
2015;(5):803-807
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the therapeutic effect of Xingnaojing Injection ( XI) combined western medicine for the treatment of septic encephalopathy (SE) . Methods A total of 60 SE patients were evenly randomized into treatment group and control group. Both groups were given routine western medicine therapy such as anti-inflammation, immunological and cerebral preventive treatment, or even mechanical ventilation, sub-hypothermia therapy, and insulin intensification therapy if necessary. Additionally, the treatment group was given intravenous drip of XI. The treatment for both groups lasted one week. Glasgow Coma Scale ( GCS) scores were observed before and after treatment for the evaluation of therapeutic effect of both groups. Moreover, the serum levels of C-reactive protein (CRP) and procalcitonin (PCT) , and the hospitalization fee and time in Intensive Care Unit were compared in both groups. Results ( 1) After treatment for one week, the improvement of GCS scores in the treatment group was superior to that in the control group ( P<0.05); the total effective rate was 90.0% in the treatment group and was 56.7% in the control group, the difference being significant ( P<0.05). ( 2) After treatment for 24 hours, serum CRP and PCT levels were decreased obviously in both groups (P<0.05), and the decrease in the treatment group after treatment for 24, 48, and 72 hours and for one week was superior to that in the control group ( P<0.05). ( 3) Hospitalization fee was less and hospitalization time in ICU was shorter in the treatment group than those in the control group ( P<0.05). Conclusion XI shows satisfactory effect on relieving illness and increasing cure rate, and on decreasing hospitalization fee and time in ICU.
